Semax

Regulatory registry

Context: Research / no approved-treatment claim
Reason / limits: FDA says human safety information is absent or limited for proposed routes.
Last source review: October 15, 2026
Review scope: FDA safety-risk source rechecked October 15, 2026. This is not an approval, treatment recommendation or fresh review of every purported-use claim.
Clinical phase: Unknown: no current trial-specific phase check is included in this registry.
Registry NDC / manufacturer: Unknown unless linked to a matched FDA package record below.

Research-only means this library makes no approved-treatment claim. Compounding context does not mean compounded-only, authorized for compounding, or legally available. Product-specific source limits control.

Regulatory sources

Original regulatory / editorial source

Read the full evidence note

FDA shortage tracker

Approval context and shortage status are separate. An NDC identifies a package; it does not establish FDA approval or permission to compound.

Unknown

Unknown: no exact single-substance FDA shortage record matched. Absence from the dataset is not proof of availability or approval.

FDA dataset: 2026-10-16. Retrieved: Oct 16, 2026, 1:45 PM CDT.

Full dated shortage record · All compound tracker entries

Matched package records (0)

Records match a single exact active substance. Route and presentation are shown separately; a record does not apply to every product or preparation.

No exact matched package records. NDC and manufacturer: Unknown. No stock claim is made.

Observed change history (0)

Observed dates are when our sync saw a source state, not when a shortage started or ended. Unchanged daily checks do not add duplicate events.

No observed status changes yet.